Eleven-year temporal trends of clinical characteristics and long-term outcomes in patients undergoing percutaneous coronary intervention for acute coronary syndrome in the Shinken database.


Journal

Heart and vessels
ISSN: 1615-2573
Titre abrégé: Heart Vessels
Pays: Japan
ID NLM: 8511258

Informations de publication

Date de publication:
Feb 2019
Historique:
received: 30 03 2018
accepted: 20 07 2018
pubmed: 26 7 2018
medline: 12 3 2019
entrez: 26 7 2018
Statut: ppublish

Résumé

Despite the increasing incidence of acute coronary syndrome (ACS) in Japan, its prognosis has improved. However, there is a paucity of longitudinal registry data providing trends of in-hospital care and prognosis of ACS in Japan. ACS patients undergoing percutaneous coronary intervention (PCI) included in the Shinken Database 2004-2014 were divided into two groups according to admission year (2004-2009, n = 390; 2010-2014, n = 328). Patient characteristics, lesion/procedure characteristics, medications at discharge, all-cause mortality, cardiovascular death, acute myocardial infarction (AMI), target lesion revascularization (TLR), re-PCI to new lesion, and coronary artery bypass graft (CABG) within 2 years after discharge were compared between the groups. Prevalence of hypertension, dyslipidemia, and dual antiplatelet/statin prescription increased significantly between periods. Usage of second-generation drug-eluting stents (DES) increased markedly between the two periods (2.6, 66.8%), while those of bare metal stents (64.4, 26.5%) and first-generation DES (25.6, 1.5%) decreased (all, p < 0.01). Two-year event-free survival rate increased for all-cause mortality (94.6-98.3%, p = 0.01), TLR (79.4-96.1%, p < 0.01), and re-PCI to new lesion (87.3-95.1%, p < 0.01). There were no significant differences in cardiovascular death, AMI, or CABG between the two periods. The event-free rates for TLR and re-PCI to new lesion in ACS patients have increased over the last decade in Japan. These observations should be confirmed in larger, longitudinal, multicenter registries.

Identifiants

pubmed: 30043155
doi: 10.1007/s00380-018-1229-y
pii: 10.1007/s00380-018-1229-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

199-207

Références

Circulation. 2001 Jul 3;104(1):19-24
pubmed: 11435332
Eur Heart J. 2005 Apr;26(8):804-47
pubmed: 15769784
Circulation. 2004 Feb 17;109(6):745-9
pubmed: 14970110
Circ J. 2008 Jun;72(6):914-20
pubmed: 18503216
Am J Cardiol. 2004 May 15;93(10):1218-22
pubmed: 15135692
Circulation. 2004 Aug 3;110(5):522-7
pubmed: 15262842
J Cardiol. 2011 Sep;58(2):116-23
pubmed: 21820280
Am Heart J. 2007 Dec;154(6):1108-15
pubmed: 18035083
Arch Cardiovasc Dis. 2010 Jun-Jul;103(6-7):363-75
pubmed: 20800800
Am Heart J. 2009 Mar;157(3):509-516.e1
pubmed: 19249422
J Cardiol. 2015 Oct;66(4):326-32
pubmed: 25578787
Am J Cardiol. 2004 Jul 1;94(1):25-9
pubmed: 15219503
Curr Med Chem Cardiovasc Hematol Agents. 2005 Jul;3(3):195-201
pubmed: 15974884
Circulation. 1998 Jun 23;97(24):2433-44
pubmed: 9641696
Circ J. 2017 Mar 24;81(4):520-528
pubmed: 28154296
Circulation. 2002 Sep 10;106(11):1390-6
pubmed: 12221058
J Am Coll Cardiol. 2008 Jul 1;52(1):71-9
pubmed: 18582638
J Am Coll Cardiol. 2013 Jun 11;61(23):e179-347
pubmed: 23639841
Eur Heart J. 2002 Feb;23(3):230-8
pubmed: 11792138
Lancet. 2002 Sep 7;360(9335):743-51
pubmed: 12241831
J Am Coll Cardiol. 2008 Nov 25;52(22):1769-81
pubmed: 19022156
Circ J. 2013;77(4):934-43
pubmed: 23502993
Circ J. 2010 Jan;74(1):93-100
pubmed: 19942783
Lancet. 1999 Aug 28;354(9180):708-15
pubmed: 10475181

Auteurs

Yoshimi Numao (Y)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan. y-numao@umin.ac.jp.

Shinya Suzuki (S)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Hiroto Kano (H)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Junji Yajima (J)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Yuji Oikawa (Y)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Shunsuke Matsuno (S)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Takuto Arita (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Naoharu Yagi (N)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Hiroaki Semba (H)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Yuko Kato (Y)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Takayuki Otsuka (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Tokuhisa Uejima (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Takeshi Yamashita (T)

Department of Cardiovascular Medicine, The Cardiovascular Institute, Nishiazabu 3-2-19, Minato-ku, Tokyo, 1060031, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH